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Antihypertensives for combating dementia?
A perspective on candidate molecular mechanisms
and population-based prevention
M Valenzuela
1,2,3, M Esler
4, K Ritchie
5,6 and H Brodaty
2,3,7
Age-related increases in prevalent dementia over the next30–40years risk collapsingmedicalresources or radically altering the
way we treat patients. Better prevention of dementia therefore needs to be one of our highest medical priorities. We propose a
perspective onthe pathologicalbasisofdementiabasedonacerebrovascular-Alzheimerdiseasespectrumthatprovidesamore
powerful explanatory framework when considering the impact of possible public health interventions. With this in mind, a
synthesis of evidence from basic, clinical and epidemiological studies indeed suggests that the enhanced treatment of
hypertension could be effective for the primary prevention of dementia of either Alzheimer or vascular etiology. In particular, we
focus on candidate preventative mechanisms, including reduced cerebrovascular disease, disruption of hypoxia-dependent
amyloidogenesis and the potential neuroprotective properties of calcium channel blockers. Following the successful translation
of large, long-term and resource-intense trials in cardiology into improved vascular health outcomes in many countries, new
multinational prevention trials with dementia-related primary outcomes are now urgently required.
Translational Psychiatry (2012) 2, e107; doi:10.1038/tp.2012.28; published online 24 April 2012
Introduction
Hypertension and dementia affect an extraordinary number of
individuals. Population-based ﬁgures suggest that one in
three adults has hypertension as deﬁned by a blood pressure
X140/90mmHg,
1 rising to 60–70% in those over 60 years of
age.
2 At the same time, about 34 million individuals are
affected by dementia worldwide, and by 2050 this is expected
toswellto100million.
3Together,thesetwoconditionsalready
account for the bulk of disease burden in modern society, and
given the continuation of the status quo, risk the viability
of modern health-care systems. For example, in Australia,
health-care spending on dementia alone will rise to $84 billion
by2060,
4morethananyotherhealthconditionandequivalent
to the total current health budget, clearly an unsustainable
scenario.
With this in mind, for the past two decades, evidence has
accumulated for and against the idea that hypertension and
dementia may be causally linked. To date there remains
no consensus, reﬂected by contradictory conclusions in
recent systematic and expert reviews.
5–8 In our opinion, at
the heart of the debate has been a false dichotomy over
presumed etiology—either Alzheimer disease (AD) or Vascular
dementia (VaD or alternatively any one of the many related
syndromes
9). Yet, as will be reviewed below, the pathogen-
esis of late-onset dementia in the wider community is likely to
originate from an interaction of cerebrovascular disease
(CVD) and AD processes and in recent years has driven a
reconceptualization of mixed dementia as a more accurate
description.
10,11
When trying to understand why antihypertensive (AHT)
treatment may help prevent dementia, it is also helpful to
consider that distinct mechanisms may apply at extreme ends
of an AD–CVD spectrum. At the CVD extreme, linkages are
seemingly straightforward: Hypertension raises risk for car-
diac disease, CVD and stroke, increasingly powerful ante-
cedents of cognitive dysfunction. AHTs may thereby protect
against dementia by averting the development of CVD and
stroke. At the other extreme, there is a signiﬁcant literature of
complex interactions between hypertension, CVD and AD.
Details of the molecular and pathophysiological links between
cerebral hypoxia, ischemic injury, aberrant beta-amyloid
processing and neuronal dysfunction are becoming clearer.
Finally, a third possible mechanism may be speciﬁc to the
calcium channel blocker (CCB) class of AHTs, which
potentially exhibit a neuroprotective mode of action indepen-
dent of either CVD, AD or their antipressor action. Here we
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The CVD–AD dementia spectrum
Even in the most specialized centers, clinically diagnosed
Alzheimer dementia patients will invariably be at risk for CVD
by virtue of one or more cardiovascular risk factors or will
exhibit CVD on ﬂuid-attenuated inversion recovery-weighted
magnetic resonance imaging. A degree of CVD is extremely
common after the age of 50
12 and refers to a collection of
distinct disease processes, including large-vessel (macro-
vascular) and small-vessel (microvascular) disease. Aggre-
gate data from a number of longitudinal studies found one or
more different types of CVD in 68% of their sample.
13 Yet
surprisingly, no imaging study has to date compared the
frequency of CVD (using magnetic resonance imaging) with
that of AD (using molecular Pittsburgh compound B (PiB)
imaging, University of Pittsburgh, PA, USA) in individuals with
probable AD dementia. Best estimates from longitudinal,
community-based postmortem brain series indicate that AD
and CVD often co-occur. The MRC CFAS (Medical Research
Council Cognitive Function and Ageing Study) found 61% of
demented individuals had AD pathology and 54% CVD.
14 A
mixed pathological basis for all-cause dementia was also the
most common ﬁnding in the Rush Memory and Aging
Project.
15 In those clinically diagnosed with probable AD
dementia,postmortemanalysis similarlyreveals highlevels of
dual AD and CVD pathology—in fact, coincident disease is
more common than pure AD.
16 The converse also appears to
follow: 30–50% of those with clinical VaD express histological
evidence of AD pathology at postmortem,
17,18 corroborated
in vivo by a recent study of subcortical VaD patients, which
foundthat31%werePiBpositive.
19Thesestudiesarelikelyto
have underestimated the true level of mixed pathology
because the standard neuropathological analyses are
relatively insensitive to microvascular disease.
In the community, the ‘default’ etiology for dementia may
therefore best approximate a mix of AD and CVD along a
spectrum. This simple idea has several implications. In the
clinic, an optimal dementia-treatment strategy may require
management of the AD process, for example via cholinester-
ase inhibitors, as well as the CVD process, by aggressive
reduction of cardiac risk factors and secondary stroke pre-
vention.
20 In the context of public health, it elevates elimina-
tion of cardiac risk factors as the pre-eminent strategy for
dementia prevention,
21 for there remain no proven methods
for prospectively retarding the AD process (see Figure 1). As
we will argue, elimination of HT is arguably the most effective
tool at our disposal for primary dementia prevention.
Pathophysiology of hypertension in late life
Hypertension in later life is characterized by a dispropor-
tionate elevation of systolic pressure, attributable to reduced
distension of the large arteries.
22 In the extreme form, this is
expressed as isolated systolic hypertension, accompanied by
normal (or even low) diastolic pressure. Beyond 50 years of
age,biophysicalpropertiesofthecentralarterieschange,with
collagenosis, loss of elastic laminae and reduced elasticity
and elastic recoil in arterial walls.
23 Consequently, in older
people, the arterial pressure wave is less damped during
ventricular systole, pressure rising more with left ventricular
ejection and falling more during diastole (because of the lost
elastic recoil). Activation of the sympathetic nervous system,
an important pathophysiological mechanism of HT in younger
patients, is not a feature in elderly patients.
24 Further, HT in
later life is not typically renin-dependent, with renin activity
commonly subnormal.
25
Unsurprisingly, HT also produces a number of vascular
changes in the brain. Most characteristically, increased
pressure in the cerebral vessels produces vascular remodel-
ing, an adaptive but ultimately pathological process that leads
to elevated resistance.
26 Pathology includes development of
lipohyalinosis, wall thickening, luminal narrowing and smooth
muscle hypertrophy.
27 These degenerative vasostructural
changes can disrupt blood ﬂow, eventually leading to focal
ischemia, perivascular edema, blood-brain barrier disruption
and, in severe cases, cortical deafferentation.
28
Effect of hypertension on brain structure and function
HT is closely associated with development of white matter
hyperintensities (WMHs) on magnetic resonance imaging.
29,30
WMHsimagemultipleneuropathologicalprocesses,including
microvascular disease, inﬂammation and blood-brain barrier
breakdown.
31–33 As the severity of WMHs increases, cogni-
tive function deteriorates. In non-demented adults, WMH
severity predicts decreased performance on a number of
cognitive domains, particularly information processing speed,
attention and executive tasks.
34,35 Furthermore, WMHs are
associated with subjective memory complaints,
36 predict the
development of severe cognitive decline
37 and independently
predict conversion from mild cognitive impairment to clinically
diagnosed AD dementia over 3 years.
38
In midlife, hypertension-related microaneurysms, microhe-
morrhages and soft exudates can be detected in vivo using
retinal scans and are associated with subtle cognitive
impairment.
39 Hypertension also increases the frequency of
‘microbleeds’ on specialized T2-weighted imaging, small
1–2mm
3 areas of hemosiderin deposition, likely due to small
hemorrhages as well as leakage of blood through damaged
blood vessels.
40 Furthermore, Arterial spin labeling magnetic
resonance imaging has revealed that HT is linked to
widespread cerebral blood-ﬂow deﬁcits, including hypoperfu-
sion of the hippocampus and several cortical areas.
41 This
may be relevant to the pathogenesis of AD, because the
Figure 1 Conceptual diagram depicting the most common type of dementia
being of mixed pathology—a combination of AD and CVD. Reducing vascular risk
factors not only will have an impact on the CVD end of the spectrum but also will
reduce dementia risk in general.
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Translational Psychiatryhippocampus is uniquely vulnerable to degeneration early in
the disease.
42,43 In Figure 2, we show an example of a
cognitively impaired HT individual with severe WMHs indica-
tive of CVD, as well as severe atrophy cortical and hippo-
campal atrophy, suggestive of an AD process. In general,
WMHs are correlated with reduced hippocampal volumes,
44
but the temporal sequencing of these two pathologies is not
clear.
Overall, there appears to be a close link between HT and
microvascular disease in the brain, the latter particularly
relevant to cognitive dysfunction in later life. One possible
mechanism by which AHT treatment may help to minimize the
occurrence of cognitive dysfunction is therefore by reducing
the incidence of microvascular disease. The PROGRESS
(Perindopril Protection Against Recurrent Stroke Study) (see
Table 1) has indeed shown that AHT leads to a signiﬁcant
reduction in WMH volume,
45 matched by a signiﬁcant
reduction in dementia incidence in those individuals who
were cognitively intact at baseline.
46 There is even stronger
evidence between CVD and AD when examining macro-
vascular disease in the form of stroke. HT doubles the
likelihood of stroke
47 and AHT treatment signiﬁcantly reduces
the chances of stroke by 30–40%.
48,49 Given that a history of
stroke is a criterion in many classic deﬁnitions of VaD, there is
a straightforward and valid argument that elimination or better
management of HT will lower VaD burden through the
prevention of CVD.
Molecular links between CVD and AD
Cerebral ischemia, hypoperfusion and hypoxia appear to be
linkedwiththedevelopmentofADpathology.Severaljournals
have dedicated entire special issues to this topic (see editions
of Journal of Alzheimer’s Disease
50 and Annals of the New
York Academy of Sciences
51)—the breadth of this work is
beyond the scope of this review. Rather, here we highlight a
few key themes and single out a possible root cause in the
form of shared regulatory control of gene-expression networks.
Early clinical data highlighted a synergistic risk between
stroke and AD dementia. A stroke increases the likelihood of
AD dementia by a factor of three
52 and the two diseases
potentiate one another, such that the likelihood of dementia
fora givenlevelofAlzheimer pathologyiseighttimeshigher in
the presence of infarction.
17 The relationship also appears
to be bidirectional, for hippocampal tissue from individuals
who died from infarction exhibits increased beta-amyloid
(Ab) pathology as well as greater expression of the APOE
protein.
53
Ischemia upregulates and deregulates the entire amyloido-
genic cascade. Animal models of ischemic injury have found
increased expression of not only Ab protein
54,55 but also its
molecular antecedent, amyloid precursor protein (APP),
54–57
and the pathological APP cleavage enzyme, beta-secre-
tase.
58,59 In humans, a detailed spatial analysis of postmor-
temtissuefromindividualswithADdementiafoundthatsenile
plaques were more likely situated near microhemorrhages
and broken capillaries than could be expected by chance,
60
hence exposing neural populations to localized hypoxia.
A study of the effects of chronic environmental hypoxia in
the APP23 transgenic AD mouse found that beta-amyloid
cleavage enzyme levels are increased by 151%, Ab40
generation by 358%, Ab42 by 185% and numbers of neuritic
plaques 1.5 times; moreover, memory performance was
impaired over and above that seen in normoxic APP23
mice.
58 A causal relationship between CVD and AD is hence
quite plausible. However, a key missing link for the ﬁeld
remainstheidentiﬁcationofthespeciﬁcmechanismsbywhich
hypoxia and ischemic injury impinges upon pathological
amyloidogenesis.
61
Origins for these links may well lie at the molecular level.
Laser dissection of hippocampal neurons obtained from indi-
viduals with pathologically conﬁrmed AD revealed 41600
gene-expression differences in comparison with control
tissue.
62 Furthermore, these researchers used a series of
novelsystemsbiology analysestoidentifyunderlyingpatterns
within this rich data set. First, AD neuron-speciﬁc gene
expression changes grouped into several distinct clusters, the
primary cluster unique for demonstrating the most coherent
changes, focused around altered protein synthesis. Interest-
ingly, functional annotation of deregulated genes within the
primary cluster found a series of AD-related gene expression
abnormalities (as expected), as well as abnormalities related
tocardiovasculardisease.Forexample,greaterexpressionof
apolipoprotein E (ApoE) was found in AD neurons and agrees
with ApoE4 as the only corroborated genetic risk factor for
sporadic AD dementia.
63 Less well known is that APOE4 also
increases the risk for cardiovascular disease by 42%.
64
Moreover, abnormal APOE expression in the brain correlated
with abnormal expression of cardiovascular disease-related
genes such as kinase deﬁcient protein (WNK1), timpmetallo-
peptidase inhibitor 1 (TIMP1) and cystathionine-beta-
synthase (CBS), as well as several coronary artery disease-
related genes. Accordingly, APOE was identiﬁed as a hub
gene within the primary cluster, maximally connected with
other gene-expression changes. Many of the 17 other hub
genes have also been implicated in both neurodegenerative
Figure 2 Fluid-attenuated inversion recovery-weighted magnetic resonance
imaging of an elderly cognitively impaired individual with severe white matter
disease (hyperintense lesions around ventricles, arrow) as well as severe
hippocampal atrophy (highlighted boxed area).
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Translational Psychiatryand vascular disease processes: microtubule-associated
protein 4 (a microtubule stabilization protein important to cell
growth and motility in both neurons and cardiocytes), serpin
peptidase inhibitor clade A, member 3 (SERPINA3,a n
enzyme regulator implicated in inﬂammatory processes
relevant to myocardial infarction
65 as well as amyloid ﬁbril
formation in AD
66) and paraoxonase 2 (PON2, a reactive
oxygen species scavenger implicated in both atherosclero-
sis
67 and AD
68). Evidently, at the neuronal level, gene-
expression changes linked to both AD and vascular disease
regularly co-occur.
ThesigniﬁcanceofAD–CVDgenecoexpressionisnotentirely
clear, and requires replication, but one possible explanation
is that coexpressed genes may also be coregulated.
62
Exploratory analysis looked for commonalities in the
upstream promoter region of those genes identiﬁed within
the primary cluster and found 26 transcription factors with
binding sites that matched the most common cis-regulatory
motifs. Some of these included transcriptional factors that
target dozens of different AD-related and CVD-related
genes, including Arnt-Ahr (crucial to activating hypoxia-
related genes) and Hand1-TCF3 (a member of the basic
helix-loop-helix family that has a very wide impact on gene
regulation). It is hence possible that CVD and AD co-occur
because abnormal protein processes in both diseases
share a common transcriptional regulatory network, and so
compromise the neurovascular unit. Further research of
this nature is highly prized as it may reveal entirely new
Table 1 Longitudinal RCTs of antihypertensives with incident dementia and cognitive outcomes
Study Initial n Nature of sample Mean follow-up
(years)
AHT class and
SBP effect
(active placebo)
Main outcomes
SYST-EUR
48 4695 Uncomplicated
hypertension in those
460 years
2 CCB±ACEi±Diu Signiﬁcant 50% reduction in
dementia incidence (AD and
AD+VaD).
Trial stopped at pre-determined
surveillance point because of 30%
risk reduction in incident stroke
 8mmHg
SYST-EUR open trial
83 4695 As above, open treatment
was offered to all in original
placebo group for a further
2 years after halting trial
4 CCB±ACEi±Diu Signiﬁcant 55% reduction in
dementia incidence in original
active treatment group
 7mmHg
MRC
14 2584 Untreated hypertension
recruited via GP practice
65–74 years of age
5.5 BB or Diu No effect on two cognitive
measures: trails A and paired
associates learning test
 16mmHg
SHEP
85 4736 Isolated systolic
hypertension in those 460
years
4.5 Diu±BB Non-signiﬁcant trend in dementia
incidence reduction
 12mmHg
PROGRESS
87 6105 History of cerebrovascular
disease within past 5 years
(hypertension was not
mandatory)
4 ACEi±Diu Signiﬁcant 31% reduction in
dementia in those initially
without cognitive impairment
 9mmHg
HOPE
88 9297 High-risk cardiovascular
patients (previous coronary
artery disease,
cerebrovascular disease,
peripheral artery disease,
diabetes and one other risk
factor aged X55.
4.5 ACEi±Vitamin E Signiﬁcant 39% reduction in
functional impairment
secondary to incident stroke
 4mmHg
HYVET-COG
6 3336 Hypertension (SBP
160–200mmHg;
DBPo110mmHg) and
aged X80 years.
2.2 Indapamide±ACEi
perindopril
Nonsigniﬁcant 14% reduction in
dementia
 15mmHg
Abbreviations: ACEi, angiotensin converting enzyme inhibitors; AHT, antihypertensive; BB, beta-blockers; CCB, calcium channel blocker; DBP, diastolic blood
pressure; Diu, diuretics; GP, general practitioner; RCT, randomized controlled trial; SBP, systolic blood pressure.
Bold highlights signiﬁcant ﬁndings.
Antihypertensives for combating dementia
M Valenzuela et al
4
Translational Psychiatryvascular pharmacological targets for combating dementia
across the CVD–AD spectrum.
Hypertension and cardiac risk factors are also dementia
risk factors
Long-term population-based cohort studies link hypertension
to increased risk for AD dementia
69 as well as VaD.
70 Two
cohorts, each with 415 years follow-up, have shown that
hypertension in middle age increases the risk of AD dementia
inlatelifebybetween100 and380%.
21,71 Inone study,midlife
hypertension increased AD dementia risk independent of
otherrisk factorssuchaselevatedcholesterolandAPOEe4.
72
Intriguingly, studies from Japan have failed to replicate a
relationship between midlife HT and AD dementia, whereas
conﬁrming links with VaD, leaving open the question of
possible cohort differences.
73,74 In later life, hypertension
may also be associated with increased risk for dementia, but
ﬁndings have not been as consistent.
69,75 A possible explana-
tion is that extended follow-up may be essential, because
blood pressure falls in the years prior to dementia onset, to
the extent that it is often similar or even lower than in non-
demented individuals.
76
Beyond hypertension, each known cardiac risk factor has
also been linked to AD dementia (and VaD), including
smoking,
77 diabetes
78 and midlife obesity.
79 Hence, there is
an inherent challenge when trying to parse the relative
contribution of hypertension from these other metabolic
disorders. On the other hand, there is emerging evidence for
dose-dependency across cardiovascular risk factors. Luch-
singer et al.
80 directly compared long-term AD dementia risk
in those with and without vascular risk factors, including
hypertension, diabetes mellitus, positive smoking history and
heart disease. Figure 3 shows the results of a multivariate
Hazard model. Compared with those with no risk factors, any
single cardiovascular factor signiﬁcantly increased risk for AD
dementia by 70%, two risk factors by 150% and three or four
risk factors by an alarming 240%. Accumulative risk for
dementia across vascular risk factors has also been reported
in an independent cohort with 20-year follow-up data.
81
Epidemiological studies are therefore beginning to suggest
thathypertension and the other cardiovascular risk factors not
only manifest a common risk for dementia but also possess
additive independent risks.
Does AHT treatment prevent dementia?
Sixlarge,longitudinal,double-blind,randomizedandplacebo-
controlled trials of AHT medication have investigated effects
on dementia incidence and cognitive decline (see Table 1).
Importantly, none of these trials was designed for the purpose
of dementia prevention, but rather for assessing primary
cardiac or stroke outcomes. Hence, baseline and follow-up
evaluation of cognition—the key variable of interest in
dementia trials—were very limited. The degree of pre-existing
cardiac disease for trial entry and the nature and combination
of speciﬁc AHTs have also varied. A quantitative meta-
analytic integration of these results is arguably premature and
may explain conﬂicting outcomes from systematic reviews.
6–8
Nevertheless, results from these trials have been very
informative.
The SYST-EUR (Systolic Hypertension in Europe) trial
produced the most emphatic results and is unique among the
AHT trials for testing CCBs as ﬁrst-line therapy. After an
average follow-up of 2 years, the trial was stopped prema-
turely because of overwhelming evidence of beneﬁt in the
active group: stroke rates had dropped by 42% and cardiac
endpoints by 26%.
82 At this time incident, dementia was also
analysed:
48 overall rates were lower than expected with only
32 new cases, mirroring low cardiac and stroke events
generally. Despite early cessation of the trial, active treatment
reduced the incident dementia rate from 7.7 cases per 1000
patient-years(py) to 3.8 cases per 1000py, a 50% relative
reduction (P¼0.05 intention-to-treat analysis, P¼0.03 per-
protocol analysis). Interestingly, all original placebo subjects
were then offered the active-therapy regime for a further
2 years of open-label follow-up.
83 At the 4-year stage
from randomization, twice as many dementia cases were
observed, and moreover, the protective effects of initial
CCB AHT treatment appeared to increase rather than
diminish: in the active group, 3.3 cases per 1000py were
observable and in the original placebo group, 7.4 cases per
1000py, a 55% relative decrease (Po0.001). Furthermore,
this protective effect was found for both clinical AD dementia
and VaD independently. The SYST-EUR trial is therefore the
only multicentre, double-blind, placebo-controlled and long-
itudinal randomized controlled trial (RCT) to provide positive
evidence—based on any medical treatment—for effective AD
dementia prevention. As summarized in Table 1, no RCT has
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Figure 3 A 5-year hazard risk for incident dementia as a function of number of
cardiovascular risk factors (adapted from text of Luchsinger et al.
80).
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the SYST-EUR trial. There are theoretical and experimental
reasons to suggest that the strong positive effects in this trial
may have been related to both antihypertension-related
mechanisms as well as neuroprotective effects unique to
CCBs (see next section).
The MRC trial of beta blockers or diuretics found an
altogether negative result on cognitive performance in a study
administered through general practitioners.
84 Interestingly,
this study produced an average systolic blood pressure
reduction twice as great as the SYST-EUR trial (that is, 16
vs 8mmHg), with no effect detected on two simple measures
ofcognition.Choiceandmethodofcognitiveassessmentmay
therefore be as critical as choice of ﬁrst-line AHT.
The remaining three large RCTs have produced mixed
results. The SHEP trial (Systolic Hypertension in the Elderly
Program) found a nonsigniﬁcant trend for a 16% reduction in
dementia incidence in the treatment group compared with
controls.
85 However, as has been noted in a subsequent
reanalyses,
86 a higher drop-out rate in the placebo group may
have biasedresults towardsthe null hypothesis, particularlyin
the context of a disease with progressive cognitive decline.
The PROGRESS trial targeted individuals with a recent
cerebrovascular history rather than hypertension per se using
a speciﬁc ACEi.
87 When analysis was restricted to those
without cognitive symptoms at baseline (84% of the original
sample), the results for prevention were in favor of a 31%
reduction in incident dementia (P¼0.02). However, when
combined data were used, including those with baseline
impairment, the result was lost (nonsigniﬁcant 12% risk
reduction). As PROGRESS was primarily designed for
evaluating the secondary prevention of stroke, dementia
associated with recurrent stroke was also investigated.
Results were positive in this respect, with ﬁndings of a 34%
reduction in risk (P¼0.03).
The HOPE (Heart Outcomes Prevention Evaluation) trial
was also designed for the secondary prevention of stroke.
88
Analysis of functional outcomes was restricted to those
incident cases of stroke in the four-and-a-half-year follow-up
phase. There were 156 new strokes in the treatment group
and 226 cases in the placebo group, a signiﬁcant 32% relative
risk reduction. Functional outcomes—including global
cognition, motor weakness, speech and swallowing—
were also better in the treatment group: 1.1% of indivi-
duals with recurrent stroke in the ramipril group had no
functional impairment in activities of daily living compared
with 1.7% in the placebo group, a signiﬁcant 39% relative
decrease.
The most recent HYVET (Hypertension in the Very Elderly)
trial was designed to assess fatal and non-fatal strokes in
response to indapamide (±ACEi perindopril) in individuals
X80 years.
49 Like the SYST-EUR trial, the Hypertension in
the Very Elderly was stopped prematurely after an average
of 2 years of follow-up because of overwhelming evidence
of positive vascular effects: the treatment group had a 30%
reduction in strokes, 39% reduction in mortality from stroke
and 21% reduction in all-cause mortality. A substudy
examining dementia and cognitive outcomes (HYVET-COG)
found a nonsigniﬁcant decrease in dementia incidence of
14%, equivalent across both VaD and AD dementia.
6 The
authors noted that their study was under-powered to detect
aneffectsizeofthismagnitude,andalsocarriedoutameta-
analysis of the ﬁeld including results from their own trial.
This most recent meta-analysis found a signiﬁcant protec-
tiveeffectofAHTsondementiaincidence,withriskreduced
by 13%.
Overall, there is imperfect but nevertheless suggestive
evidencethatAHTtreatmentmayhaveausefulroleinhelping
prevent dementia and age-related cognitive impairment. To
date, only a single RCT has speciﬁcally found a protective
effect for incident AD dementia, and so further trials of this
kind are urgently required, designed intentionally to assess
incident dementia. Because a number of trials have been
required to stop prematurely because of overwhelming
positive effects on myocardial and cerebral infarction, use of
placebo arms are no longer justiﬁable. Rather, dose-ﬁnding or
head-to-head drug comparisons could be employed. But
which AHT to use? Below, we brieﬂy outline the beneﬁts for
considering CCBs as ﬁrst-line treatment.
Candidate CNS mechanisms
Neuroprotective properties of CCBs. Several cohort
studies have noted lower rates of dementia (including AD
dementia) in individuals treated for hypertension compared
with those never exposed to AHTs.
69,89 Furthermore, a more
recent study has established that each year of AHT use is
linked with an 8% reduction in prospective dementia risk in
individuals o75 years of age.
90 The question therefore arises
whether AHTs may have an intrinsic neuroprotective mode of
action?
Experimental studies suggest CCBs may possess neuro-
protective properties. For example, cultured neurons are
protected in vitro from the effects of hypoxia when pretreated
with CCBs.
91,92 Animal models of ischemia also exhibit CCB-
dependent neuroprotection in vivo,
93,94 with particularly
interesting ﬁndings in spontaneously HT rats.
95 These
animals exhibit widespread neuronal loss, including in
hippocampus and cortical regions. Treatment with a blood
pressure-lowering dose of nicardipine (3mgkg
 1)r e s c u e d
hypertension-related neuronal damage.
96 Interestingly, a
non-hypotensive dose (0.1mgkg
 1) was also sufﬁcient to
rescue neuronal numbers in the frontal lobe and protects
neuronal loss in the hippocampus. In contrast, the loop
diuretic hydrazaline was ineffectual, despite equivalent
antipressor action. Potential neuroprotective effects of
CCBs may well be independent of their effect on blood
pressure, and rather reﬂect their effect on calcium meta-
bolism.
Dysfunction of intracellular calcium metabolism is widely
implicated in brain ageing, ischemia and AD.
97,98 Interaction
of the classic AD-related molecule, beta-amyloid (Ab), with
theneuronal plasma membraneleads toelevatedintracellular
calcium and consequent excitotoxicity.
99,100 The potentially
more lethal oligomeric Ab species also disrupt the cell
membrane to produce calcium-mediated toxicity in vitro.
101
Calcium metabolism may thereby undergo a ‘double hit’ in the
context of hypertension because consequent neuronal injury
also leads to calcium pump failure.
102,103
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vulnerable neuronal populations by normalizing calcium
metabolism, in addition to attenuating the development of
CVD through their antipressor action. A dual mode of action is
also supported by the ﬁndings of the SYST-EUR study—
unique for using CCBs as ﬁrst-line AHT therapy—which of all
the RCTs found the strongest preventative effects.
83 A dual
mode of action is hence an interesting hypothesis, but will
require more research. In particular, new studies are required
using CCBs as ﬁrst-line therapy or inclusion as a comparison
arm in head-to-head trials. To speciﬁcally test a potential
neuroprotective mechanism, a subtherapeutic trial of CCBs in
normotensive individuals using neuroimaging outcomes
would be of high interest.
AHTs as AD modiﬁers. Provocatively, results from one
study suggest that several different AHTs may be effective in
attenuating the development of Ab pathology.
104 In this
study, 55 different AHT medications were ﬁrst screened in a
high-throughput system to analyze their effect on in vitro
production of Ab1 40 and Ab1 41. Seven different AHT drugs,
from across the class spectrum, were found to signiﬁcantly
reduce Ab production by cultured embryonic neurons.
Because the main neurotoxic Ab species may include soluble
oligomers,
105 these seven compounds were further screened
using an oligomerization assay. Only valsartan, an angio-
tensin receptor blocker, signiﬁcantly prevented the polymeri-
zation of monomeric Ab1-41 into Ab oligomers. Next,
6-month-old transgenic Tg2576 AD mice were treated for
5 months with valsartan at subtherapeutic doses. Accordingly,
blood pressure in these animals was unchanged. However,
in mice killed at 11 months of age, oligomeric Ab was
reduced by 2–3 times and insoluble Ab plaques by
50–75%. Furthermore, animals were beneﬁted from impro-
ved spatial working memory. Although the mechanism of this
action is unknown, an increase in insulin-degrading enzyme
protein in the brains of treated animals suggests a possible
amyloid breakdown and clearance effect. These interesting
data, however, have not been replicated in a subsequent
study that also tested valsartan,
106 possibly because a
different transgenic mouse model was studied (3xTGAD),
and were killed at a younger age (6 months), prior to the age
of development of signiﬁcant AD pathology.
Surprisingly,arecentautopsyserieshasfoundevidencefor
possible disease-modifying effects in humans.
107 This group
compared AD pathology at postmortem in demented indivi-
duals with those who had untreated hypertension, treated
hypertension or normal blood pressure prior to death. Results
are difﬁcult to interpret because dementia severity was
different between groups, but nevertheless it was surprising
that the treated HT group had signiﬁcantly less neuropathol-
ogy than even the normotensive group. There is hence
an intriguing possibility that AHT medication may exert an
AD-modifying role in humans as it may in rodent models, an
idea well suited to further testing with PiB imaging methods.
A hypothetical disease and prevention pathway
Arguably the most controversial idea in the area is that CVD
and AD are not spontaneously parallel pathologies but rather
that CVD promotes and precedes development of AD.
In Figure 4, we propose a hypothetical disease pathway.
It begins with hypertension in midlife, itself an endpoint in an
idiopathic and multifactorial disease process. Hypertension
drives two major brain changes. First, cerebral angiopathy,
which at the macroscopic scale resembles that of coronary
artery disease and in the most severe form can lead to stroke,
while at the microscopic scale, arteriolar and capillary disease
in subcortical areas is already highly prevalent by the age of
50 years.
12 Second, these structural changes lead to dynamic
vascular changes, the most relevant being a signiﬁcant
reduction in cerebral blood ﬂow in the hippocampus.
41
Capillary wall damage may be most severe in the hippocam-
pus, for it is a part of the brain with the greatest vessel
tortuosity.
60 Microhemorrhages appear here ﬁrst,
108 leading
to localized microbleeds, hypoxia and neuronal and synaptic
damage—the latter is the most faithful biological correlate of
clinical symptoms
109,110 andsomaycoincide withthe onsetof
amnestic problems that are the ﬁrst clinical sign of incipient
dementia. In parallel and perhaps temporally offset, hypoxia
potentiates all parts of the amyloidogenic cascade,
58 further
exacerbated by ischemic excitotoxic and inﬂammatory
byproducts. Beta-amyloid is itself vasconstrictive,
111 and
so propagates a vicious cycle. As alluded to, these two
pathological processes may be joined at a fundamental
molecular level, with vulnerable hippocampal neurons ex-
hibiting both AD-related and CVD-related gene expression
abnormalities. By the time the individual comes to postmor-
tem, there will be a convergence of AD and CVD pathology in
the brain.
Following the logic of this schema, AHT medication
may have three main beneﬁts that together help prevent
and delay dementia onset. First, hypertension is addressed
at outset, reducing the degree of vascular remodeling
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Figure 4 The hypothetical disease pathway for development of mixed
dementia. AHT medication may have three hypothetical preventative actions:
direct antipressor effects, neuroprotection and disease modiﬁcation.
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to cerebral blood ﬂow. This in turn leads to decreased
development of microbleeds, microischemia, infarction,
and ultimately, reduced synaptic loss. Second, CCBs
may be neuroprotective by stabilizing calcium meta-
bolism and also by blocking Ab-dependent vasoconstric-
tion.
111 Third, some AHTs may also act as possible
disease modiﬁers, and so directly decrease Alzheimer
pathology.
Conclusions
Control of hypertension is one of the adult medicine’s ﬁnest
preventative treatments, reducing the incidence of stroke and
heart attack by between 30 and 40%. For this reason alone,
AHTs may have a role in the better prevention of dementia,
especially at the CVD end of the spectrum. Many pieces of
evidence suggest that AHTs may also have a positive impact
against dementia at the AD end of the spectrum. First, AD and
CVD are most likely to be fundamentally connected, with
evidence of a shared gene regulatory network, frequent
coexpression on postmortem analysis, and as well the
accumulation of dementia risk across vascular risk factors.
Second, clinical trials indicate that AHTs can help combat
incidentdementia,onemultinationalRCTofCCBsspeciﬁcally
ﬁnding a preventative effect on AD dementia. Because the
etiology for dementia in the community is most often a mix of
AD and CVD pathology, the relevance of AHT treatment to
dementia prevention is in general likely to be greater than
previously acknowledged. At a mechanistic level, there are
several plausible biological pathways that may be involved,
none so far deﬁnitive. Primary prevention of stroke and
microvascular disease is the logistical ﬁrst candidate. In
addition, CCBs may beneﬁt from a neuroprotective mode of
action that is unrelated to their effect on blood pressure. More
speculatively, AHTs may interfere with amyloid pathogenesis
by reducing hypoxia-dependent enzymatic cleavage of
amyloid precursor protein or with greater amyloid breakdown
and clearance. AHTs may therefore help combat against
dementia by CVD- and AD-related mechanisms, as well as
through neuroprotection.
Overall, the multiple lines of evidence reviewed here
suggest that better management of hypertension could be
effectiveforthepreventionofdementia.Giventheforecastsof
a global dementia epidemic to accompany the graying of
modern nations, better hypertension control may well turn out
to also be one of the most important preventative tools of
psychiatry and neurology. Several lacunae exist in our
current state of knowledge, including a molecular basis for
how CVD may lead to AD and a better distinguishing signal
from noise in longitudinal epidemiological studies. Perhaps
the most glaring deﬁcit is the absence of large-scale RCTs
orientated towards dementia prevention outcomes—these
are urgently needed. In this regard, the ﬁeld could learn
from a history of long-term, resource-intensive, transna-
tional and multicentre prevention trials in cardiology, and
indeed may proﬁt by a closer collaboration between heart
and brain specialists.
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